Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 7, 2026
Creative Medical Technology Holdings, Inc. (CELZ) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $1.5 million.
Revenue
$0
Net income
$-1.51M
-22.6% vs year-ago quarter
Operating cash flow
$-1.47M
-27.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.41
+14.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.59M
+155.5% vs year-ago quarter
Net cash
—
Operating margin
-208004.4%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CELZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Phoenix, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1187953
- Former names
- JOLLEY MARKETING INC (until May 13, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3,000 | $0 | $0 |
| Operating income | -$1.6M | -$1.5M | -$1.9M | -$1.3M | -$1.3M |
| Net income | -$1.5M | -$1.4M | -$1.9M | -$1.2M | -$1.2M |
| Diluted EPS | -$0.41 | -$0.38 | -$0.70 | -$0.48 | -$0.48 |
| Operating cash flow | -$1.5M | -$1.3M | -$1.9M | -$1.2M | -$1.2M |
| Total assets | $9.4M | $6.4M | $7.8M | $5.9M | $7.1M |
| Total liabilities | $698,595 | $307,649 | $284,880 | $261,353 | $277,644 |
| Stockholders' equity | $8.7M | $6.1M | $7.5M | $5.6M | $6.8M |
| Cash and investments | $8.7M | $5.7M | $7.2M | $5.4M | $6.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 31, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 24, 2026 | Dec 31, 2025 |
All 409 Creative Medical Technology Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.